nach oben

Erschienen in:

01.12.2009

Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment

verfasst von: Ana Paula M. Casarini, Raquel S. Jallad, Emília M. Pinto, Iberê C. Soares, Suely Nonogaki, Daniel Giannella-Neto, Nina R. Musolino, Venâncio A. F. Alves, Marcello D. Bronstein

Erschienen in: Pituitary | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

About one-third of acromegalics are resistant to the clinically available somatostatin analogs (SA). The resistance is related to density reduction or different expression of somatostatin receptor subtypes (SSTR). This study analyzes SSTR’s expression in somatotrophinomas, comparing to SA response, hormonal levels, and tumor volume. We analyzed 39 somatotrophinomas; 49% were treated with SA. The most expressed SSTR was SSTR5, SSTR3, SSTR2, SSTR1, and SSTR4, respectively. SSTR1 and SSTR2 had higher expression in patients that had normalized GH and IGF-I. SSTR3 was more expressed in patients with tumor reduction. There was a positive correlation between the percentage of tumor reduction and SSTR1, SSTR2 and SSTR3 expression. Also, a positive correlation between SSTR2 mRNA expression and the immunohistochemical reactivity of SSTR2 was found. Our study confirmed the association between the SA response to GH and IGF-I and the SSTR2. Additionally, this finding was also demonstrated in relation to SSTR1.

Brazeau P, Vale W, Burgus R et al (1973) Hypotalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179(8):77–79. doi:10.1126/science.179.4068.77 CrossRefPubMed

Moller LN, Stidsen CE, Hartmann B et al (2003) Review: somatostatin receptors. Biochim Biophys Acta 1616:1–84. doi:10.1016/S0005-2736(03)00235-9 CrossRefPubMed

Schonbrunm A, Tashjian H Jr (1978) Characterization of functional receptors for somatostatin in rat pituitary cells in culture. J Biol Chem 253(18):6473–6483

Reisine T, Bell G (1995) Molecular biology of somatostatin receptors. Endocr Rev 16:427–442PubMed

Hofland LJ, Lamberts S (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28–47. doi:10.1210/er.2000-0001 CrossRefPubMed

Taboada GF, Luque RM, Bastos W et al (2007) Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156:65–74. doi:10.1530/eje.1.02313 CrossRefPubMed

Ballare E, Persani L, Lania AG et al (2001) Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 86(8):3809–3814. doi:10.1210/jc.86.8.3809 CrossRefPubMed

Barlier A, Boullier LP, Gunz G et al (1999) Impact of gsp oncogene on expression of genes coding for Gsa, Pit-1, Gi2a, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J Clin Endocrinol Metab 84:2759–2765. doi:10.1210/jc.84.8.2759 CrossRefPubMed

Danila DC, Haidar JNS, Zhang X et al (2001) Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. Clin Endocrinol Metab 86:2976–2981. doi:10.1210/jc.86.7.2976 CrossRef

10.

Elberg G, Hipkin W, Schonbrunn A (2002) Homologus and heterologus regulation of somatostatin receptor 2. Mol Endocrinol 16:2502–2514. doi:10.1210/me.2002-0207 CrossRefPubMed

11.

Greenman Y, Melmed S (1994) Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79:724–729. doi:10.1210/jc.79.3.724 CrossRefPubMed

12.

Teijeiro R, Rios R, Costoya J et al (2002) Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. Cell Physiol Biochem 12:31–38. doi:10.1159/000047824 CrossRefPubMed

13.

Csaba Z, Dournaud P (2001) Cellular biology of somatostatin receptors. Neuropeptides 35:1–23. doi:10.1054/npep.2001.0848 CrossRefPubMed

14.

Freda PU, Katznelson L, Van der Lely AJ et al (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90:4465–4473. doi:10.1210/jc.2005-0260 CrossRefPubMed

15.

Jallad RS, Musolino NR, Salgado LR et al (2005) Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 63:168–175. doi:10.1111/j.1365-2265.2005.02317.x CrossRef

16.

Bronstein M, Musolino N, Jallad R et al (2005) Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (Oxf) 63:514–519. doi:10.1111/j.1365-2265.2005.02372.x CrossRef

17.

Freda PU (2002) Clinical review 150: somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87(7):3013–3018. doi:10.1210/jc.87.7.3013 CrossRefPubMed

18.

Lamberts SWJ, Lely V, Hofland LJ (2002) New somatostatin analogs: will they fulfil old promises? Eur J Endocrinol 146:701–705. doi:10.1530/eje.0.1460701 CrossRefPubMed

19.

Petersenn S, Heynes M, Ludecke DK et al (2000) Absence of somatostatin receptor type 2A mutation and Gip ongogene in pituitary somatotroph adenomas. Clin Endocrinol (Oxf) 52:35–42. doi:10.1046/j.1365-2265.2000.00880.x CrossRef

20.

Petersenn S, Rasch AC, Bonhke et al (2002) Identification of an upstream pituitary-active promoter of human somatostatin receptor subtype 5. Endocrinology 143:2626–2634. doi:10.1210/en.143.7.2626 CrossRefPubMed

21.

Saveanu A, Lavaque E, Gunz G et al (2002) Demonstration of enhanced potency of a chimeric somatostatin–dopamine molecule, BIM-23 A 387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenomas cells. J Clin Endocrinol Metab 87:5545–5552. doi:10.1210/jc.2002-020934 CrossRefPubMed

22.

Saveanu A, Gunz G, Dufour H et al (2001) BIM-23244, a somatostatin receptor subtype 2 and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide—resistant human GH secreting adenomas. J Clin Endocrinol Metab 86:140–145. doi:10.1210/jc.86.1.140 CrossRefPubMed

23.

Jallad RS, Musolino NR, Kodaira S et al (2007) Does partial surgical tumor removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol (Oxf) 67(2):310–315. doi:10.1111/j.1365-2265.2007.02885.x CrossRef

24.

Antonov J, Goldstein DR, Oberli A et al (2005) Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization. Lab Invest 85(8):1040–1050. doi:10.1038/labinvest.3700303 CrossRefPubMed

25.

Ponchel F, Toomes C, Bransfield K et al (2003) Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol 13:3–18

26.

Jaquet P, Saveanu A, Gunz G et al (2000) Human somatostatin receptors subtypes in acromegaly: distinct patterns of menssenger ribonucleic acid expression and hormone suppression identify distinct tumoral phenotypes. J Clin Endocrinol Metab 85:781–792. doi:10.1210/jc.85.2.781 CrossRefPubMed

27.

Panetta R, Patel YC (1995) Expression of mRNA for all five human somatostatin receptors (hSSTR1–5) in pituitary tumors. Life Sci 56:333–342. doi:10.1016/0024-3205(94)00956-2 CrossRefPubMed

28.

Miller GM, Alexander JM, Bikkal HA et al (1995) Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 80:1386–1392. doi:10.1210/jc.80.4.1386 CrossRefPubMed

29.

Greenman Y, Melmed S (1194) Heterogenous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 78:398–403. doi:10.1210/jc.78.2.398 CrossRef

30.

Lamberts SW, Krenning EP, Reubi JC (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12:450–482. doi:10.1210/edrv-12-4-450 CrossRefPubMed

31.

Lamberts SW, Lely AJVL, Herder WW et al (1196) Octreotide. N Engl J Med 334:246–254. doi:10.1056/NEJM199601253340408 CrossRef

32.

Florio T, Thellung S, Corsaro A et al (2003) Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf) 59:115–128. doi:10.1046/j.1365-2265.2003.01811.x CrossRef

33.

Hofland LJ, Hoek JVD, Koetsveld PMV et al (2004) The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone and prolactin secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89(4):1577–1585. doi:10.1210/jc.2003-031344 CrossRefPubMed

34.

Park C, Yang I, Woo J et al (2004) Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous SRIF activity and response to Octreotide. Endocr J 51(2):227–236. doi:10.1507/endocrj.51.227 CrossRefPubMed

35.

Lissett CA, Shalet SM (2000) Management of pituitary tumours: strategy for investigation and follow-up. Horm Res 53(3):65–70. doi:10.1159/000023537 CrossRefPubMed

36.

Colao A, Ferone D, Marzullo P et al (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–152. doi:10.1210/er.2002-0022 CrossRefPubMed

37.

Etxabe J, Gaztambide S, Latorre P et al (1993) Acromegaly: an epidemiological study. J Endocrinol Invest 16:181–187PubMed

38.

Thodou E, Kontogeorgos G, Theodossiou D et al (2006) Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol 59:274–279. doi:10.1136/jcp.2005.026914 CrossRefPubMed

39.

Ezzat S, Kontogeorgos G, Redelmeier DA et al (1995) In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol 133(6):686–690. doi:10.1530/eje.0.1330686 CrossRefPubMed

40.

Van Der Lely AJ, Harris AG, Lamberts SW (1992) The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol (Oxf) 37:181–185. doi:10.1111/j.1365-2265.1992.tb02304.x CrossRef

41.

Yang IM, Woo JT, Kim SW et al (1995) Characteristics of acromegalic patients with good response to octreotide, a somatostatin analogue. Clin Endocrinol (Oxf) 42(3):295–301. doi:10.1111/j.1365-2265.1995.tb01878.x CrossRef

42.

Jaquet P, Gunz G, Saveanu A et al (2005) Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 153:135–141. doi:10.1530/eje.1.01950 CrossRefPubMed

43.

Hofland LJ, Lamberts SW (2004) Somatostatin receptors in pituitary function, diagnosis and therapy. Front Horm Res 32:235–252. doi:10.1159/000079048 CrossRefPubMed

44.

Bronstein MD (2006) Acromegaly: molecular expression os somatostatin receptor subtypes and treatment outcome. Front Horm Res 35:129–134. doi:10.1159/000094315 CrossRefPubMed

45.

Newman CB, Melmed S, George A et al (1998) Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 83:3034–3040. doi:10.1210/jc.83.9.3034 CrossRefPubMed

46.

Bevan JS (2005) The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856–1863. doi:10.1210/jc.2004-1093 CrossRefPubMed

47.

Cozzi R, Attanasio R, Montini M et al (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090–3098. doi:10.1210/jc.2003-030110 CrossRefPubMed

48.

Matrone C, Pivonello R, Colao A et al (2004) Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology 79:142–148. doi:10.1159/000077272 CrossRefPubMed

49.

Zatelli MC, Piccin D, Tagliati F et al (2003) Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH and PRL secretion. J Clin Endocrinol Metab 88:2797–2802. doi:10.1210/jc.2002-021825 CrossRefPubMed

50.

Olias G, Viollet C, Kusserow H et al (2004) Regulation and fuction os somatostatin receptors. J Neurochem 89:1057–1091. doi:10.1111/j.1471-4159.2004.02402.x CrossRefPubMed

51.

Casarini AP, Pinto EM, Jallad RS et al (2006) Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest 29(9):826–830PubMed

52.

Resmini E, Dadati P, Ravetti JL et al (2007) Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting Octreotide in an acromegalic patient. J Clin Endocrinol Metab 92(5):1592–1599. doi:10.1210/jc.2006-2084 CrossRefPubMed

Titel: Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment
verfasst von: Ana Paula M. Casarini
Raquel S. Jallad
Emília M. Pinto
Iberê C. Soares
Suely Nonogaki
Daniel Giannella-Neto
Nina R. Musolino
Venâncio A. F. Alves
Marcello D. Bronstein
Publikationsdatum: 01.12.2009
Verlag: Springer US
Erschienen in: Pituitary / Ausgabe 4/2009
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-009-0175-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Gegen postoperative Darmmotilitätsstörung: Erster Kaffee schon im Aufwachraum

Frauen bekommen seltener eine intensive Statintherapie

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

Prevalence and clinical demographics of cerebral salt wasting in patients with aneurysmal subarachnoid hemorrhage

Lymphocytic hypophysitis with associated thyroiditis in a man with aseptic meningitis

Effects of physical training on serum and pituitary growth hormone contents in diabetic rats

Efficacy of long-term lanreotide treatment in patients with acromegaly

Utility of single luteinizing hormone determination 3 h after depot leuprolide in monitoring therapy of gonadotropin-dependent precocious puberty

The diagnostic value of fused positron emission tomography/computed tomography in the localization of adrenocorticotropin-secreting pituitary adenoma in Cushing’s disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Gegen postoperative Darmmotilitätsstörung: Erster Kaffee schon im Aufwachraum

Frauen bekommen seltener eine intensive Statintherapie

Update Innere Medizin